Evaluating the Expression of Oct4 as a Prognostic Tumor Marker in Bladder Cancer

Nasim Hatefi1,2, Nazila Nouraee1, Mahmoud Parvin2, Seyed-Amir Mohsen Ziaee3, Seyed Javad Mowla*1

Abstract

Objective(s)
The key transcriptional regulator Oct4 is one of the self-renewal and differentiation-related factors in cancer stem cells, where it maintains “stemness” state. Cancer stem cells have been identified in a variety of solid malignancies. They are a small population of tumor cells with stem cell characteristics, which are a likely cause of relapse in cancer patients. Due to high incidence, mortality, and recurrence rates of bladder cancer and the necessity of accurate prediction of malignant behavior of the tumors, we evaluated the prognostic value of Oct4 expression in formalin-fixed paraffin-embedded (FFPE) tissues of bladder cancer.

Materials and Methods
In this study, Oct4 expression was evaluated in 52 (FFPE) tissues of bladder cancer. RNA extraction from samples of 30 patients from the archive of Labbafi-Nejad Medical Centre in Tehran was performed and Oct4 expression levels were examined by semi-quantitative RT-PCR. The intracellular distribution of Oct4 protein was also determined by immunohistochemistry (IHC).

Results
The results revealed a significant correlation between the expression level of Oct4 and the tumors’ grade and stage. A mostly cytoplasmic distribution of Oct4 protein was also confirmed by IHC.

Conclusion
All together, our data indicate that the expression level of Oct4 gene is correlated with the clinical and histopathological prognostic indexes of tumors and thus can be considered as a potential prognostic tumor marker.

Keywords: Bladder cancer, Cancer Stem cell, Oct4, Prognosis

1 Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
*Corresponding author: Tel: +98-21-82883464; Fax: +98-21-82884717; email: sjmowla@modares.ac.ir
2 Department of Pathology, Labbafi-Nejad Medical Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Urology and Nephrology Research Centre, Labbafi-Nejad Medical Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Introduction

Tumor recurrence and multifocality are two common features of bladder tumors. Moreover, several previous reports suggest that these tumors are derived from a primary transformed progenitor cell (1, 2). Based on Cancer Stem Cell model, CSCs are characterized by self-renewal, heterogeneity (potential for multidirectional differentiation), resistance to apoptosis, and resistance to conventional therapies. Therefore, CSC concept has fundamentally changed our understanding of tumor development and progression as well as the diagnostic and therapeutic approaches. Nowadays, CSCs have been isolated from a variety of solid tumors such as breast cancer, lung, prostate, colon, and brain tumors (3-9). The most important members of CSCs' regulatory core are transcription factors such as Oct4, Sox2, and Nanog, which are defined as key players in the regulatory network for maintaining the “stemness” state of stem cells (8, 10-12).

Oct4 (POU5f1), a member of POU family, is a transcription factor that is required for pluripotency during early embryogenesis and the maintenance of embryonic stem (ES) cell and pluripotent cell identity. Oct4 expression is strongly repressed following stem cell differentiation (12-17). In somatic cells, Oct4 expresses only in rare sub-populations of multipotent cells with high self-renewal capacity, such as the tissue-specific adult stem cells in normal tissues or cancer stem cells in tumor samples (12, 18, 19). Oct4 has a variety of functions: it can either act as suppressor for genes involved in differentiation or act as a trans-activator for self-renewal genes (20).

Based on our previous work, misexpression of Oct4 is correlated with tumorigenesis and can affect the behavior of tumors such as recurrence or resistance to therapy (10, 15).

Considering the necessity of using new molecular markers to accurately predict the malignance behavior of bladder tumors, we evaluated the prognostic value of Oct4 expression, as a well-known stem cell molecular marker, in FFPE samples of bladder tumor tissues by means of semi-quantitative RT-PCR and immunohistochemistry (IHC).

Materials and Methods

FFPE blocks collection

FFPE samples (52 blocks of 30 patients) of bladder tumors belonging to patients who had been referred to the Shahid Labbafi-Nejad Medical Centre in Tehran before 2006, were obtained from archival collection of pathology department. After surveying the patients’ medical history, samples were selected and categorized according to the histological characteristics based on H&E slides by an expert pathologist. Samples with no or less than 20% of normal tissue presence were selected for the experiments. Moreover, tissues with hemorrhagia were excluded from our analysis due to their low RNA quality (Table 1).

RNA extraction

7-10× 10 µm-thick sections of each block were deparaffinized with xylene following rehydration with ethanol. Then tissues were digested with optimized concentration of proteinase K (Fermentase, Vilninus, Lithuania) in order to remove the protein cross links with cellular RNA. Then samples were treated with RNX Plus Solution (Cinnagen, Iran) and RNA extraction procedure were performed according to the manufacturer’s instructions.

Reverse transcription-PCR (RT-PCR)

Due to the existence of processed pseudogenes of Oct4, all extracted total RNAs were treated with RNase-free DNase (Fermentase, Lithuania). For cDNA synthesis, random hexamer primers and RevertAid™ M-MuLV reverse transcriptase (Fermentase, Lithuania) were used according to the manufacturer’s instructions. We also prepared a No-RT control sample for each reaction to detect any potential contamination with genomic DNA.
## Table 1. A brief clinico-pathological description of patients

| No. | Age/Sex | Code and number of block | Grade | Stage | Oct4 expression rate | Radical cystectomy (Date & number of block) | Survival status |
|-----|---------|--------------------------|-------|-------|----------------------|---------------------------------------------|-----------------|
| 1   | 66/F    | 79-2453                  | II    | T1    | High                 | No                                         | 8/28/2006       |
| 2   | 75/F    | 84-347                   | I     | T1    | Low                  | No                                         | Alive           |
| 3   | 63/F    | 79-1258                  | II    | T1    | High                 | No                                         | Alive           |
| 4   | 46/M    | 79-2698                  | II    | T1    | Low                  | Oct 28, 2012, (2755)                       | 2001            |
| 5   | 46/M    | 80-51                    | I     | T1    | Low                  | No                                         | Alive           |
| 6   | 66/M    | 79-2704                  | II    | T1    | High                 | No                                         | Alive           |
| 7   | 44/M    | 79-877                   | I     | T1    | Low                  | Dec 10, 2002                               | Alive           |
| 8   | 53/M    | 80-1292                  | I     | T1    | High                 | No                                         | 1/2/2006        |
| 9   | 81/M    | 83-1128                  | I     | T1    | Low                  | No                                         | Alive           |
| 10  | 76/M    | 81-2693                  | I     | T1    | Low                  | No                                         | Alive           |
| 11  | 52/M    | 80-121                   | I     | T1    | High                 | No                                         | Alive           |
| 12  | 81/M    | 81-3619                  | I     | Ta or Tis | High       | No                                         | Alive           |
| 13  | 63/F    | 79-3304                  | I     | T1    | Low                  | No                                         | Alive           |
| 14  | 76/M    | 80-426                   | III   | T1    | High                 | May 21, 2001, (533)                         | Alive           |
| 15  | 51/F    | 78-501                   | II    | T1    | High                 | High                                       | Partial         |
|     |         |                          |       |       |                      | Jul 13, 1999- (699)                        | 2001            |
| 16  | 66/M    | 80-2728                  | III   | T1    | High                 | High                                       | Cystoprostatectomy- |
|     |         |                          |       |       |                      |                                             | Feb 9, 2002     |
| 17  | 79/F    | 83-758                   | I     | Ta    | Low                  | No                                         | Alive           |
| 18  | 46/M    | 83-1109                  | I     | Ta    | Low                  | No                                         | Alive           |
|     |         |                          |       |       |                      |                                             | Alive           |
| 19  | 68/F    | 79-1230                  | I     | T1    | High                 | No                                         | Alive           |
| 20  | 58/M    | 80-1766                  | I     | T1    | Low                  | No                                         | 12/14/2003      |
|     |         |                          |       |       |                      |                                             |                 |
| 21  | 66/M    | 84-2231                  | I     | T1    | Low                  | Partial-Apr 26, 2007                       | Alive           |
|     |         |                          |       |       |                      |                                             |                 |
| 22  | 63/M    | 83-1689                  | II    | T1    | High                 | No                                         | Alive           |
| 23  | 31/F    | 85-2238                  | I     | T1    | Low                  | No                                         | Alive           |
| 24  | 56/M    | 84-3588                  | II    | T1    | High                 | Dec 17, 2006, (2401)                       | Alive           |
| 25  | 74/M    | 84-1199                  | II    | T1    | High                 | No                                         | Alive           |
| 26  | 67/M    | 82-2973                  | III   | T1    | High                 | No                                         | Alive           |
| 27  | 63/F    | 85-2027                  | I     | Ta    | Low                  | 0                                          | No              |
| 28  | 66/F    | 84-2689                  | I     | Ta    | Low                  | No                                         | Alive           |
| 29  | 64/M    | 83-38                    | I     | Ta    | High                 | No                                         | Alive           |
| 30  | 77/M    | 79-1407                  | II    | T1    | High                 | No                                         | 11/29/2004      |

F: Female; M: Male
Because of fragmentation of RNA molecules in FFPE samples, we designed specific primers for short segments (<300 bp) of RNA. The specific primers for Oct4 and beta2-microglobulin ($\beta 2m$), as an internal control (accession numbers: NM_002701 and NM_004048, respectively) were designed by Genrunner software (Version 3.05, Hastings Software Inc.) and synthesized by MWG-biotech (Germany), as high-purified salt-free grade. The sequences of the designed primers are as follows:

**beta2-microglobulin:**
- Forward primer: 5'- CTA CTC TCT TCT TCT GGC CTG CT -3'
- Reverse primer: 5'- GAC AAG TCT GAA TGC TCC AC - 3'

These primers amplified a 191 bp segment of human $\beta 2m$ complementary DNA.

**Oct4:**
- External forward primer: 5'- TCC CAG GAC ATC AAA GCT CT -3'
- External reverse primer: 5'- TCA TTG TTG TCA GCT TCC TCC -3'

These primers amplified a 238 bp segment of human Oct4 complementary DNA.

**Oct4 nested primers:**
- Internal forward primer: 5'- CAT CAA AGC TCT GCA GAA AG -3'
- Internal reverse primer: 5'- CTT CCT CCA CCC ACT TCT G -3'

The product of amplification of these nested primers is a 217 bp segment.

All designed primers were blasted with human genome to make sure they are not complementary to other regions of the genome (21). In case of $\beta 2M$, serial dilutions of primary PCR products were used to optimize the amount of template required for the second round without reaching to the threshold level.

PCR was performed using 2 μl of synthesized cDNA with 0.2 μl of Taq polymerase (5 unit/μl, Cinnagen, Iran), as described elsewhere (22). The PCR reaction conditions which were repeated for 37 cycles ($\beta 2m$ and Oct4-round 1) or 30 cycles (Oct4-round 2), were as follows:
- Initial denaturation at 94°C for 4 min, denaturation at 94°C for 40 sec, annealing at 57°C ($\beta 2m$ and Oct4-round2) or 55 °C (Oct4-round1) for 45 sec, extension at 72°C for 60 sec, and a final extension at 72°C for 10 min.

PCR products were separated by electrophoresis on 1.5% agarose gels, stained with ethidium bromide, and visualized by Gel Documentation (Uvitech, England).

**Statistical analysis**
All experiments were replicated two or three times and the RT-PCR results were analyzed by performing Mann-Whitney and ANOVA tests to determine the difference of Oct4 expression among different groups (SPSS software for windows, version 11, Chicago). Statistical significance was set as $P < 0.05$ and all reported $P$-values were 2-sided.

**Immunohistochemistry**
The IHC procedure was optimized using tissue samples which had been proven to be Oct4-positive by means of RT-PCR in the previous stage. Five μm-thick sections of each block were deparaffinized and rehydrated. For antigen retrieval, tissue sections were boiled in citrate buffer (10 mM, pH 6.0) for 10 min. Endogenous peroxidase activity was blocked with 1.5% H$_2$O$_2$ for 30 min, and background staining was eliminated with blocking proteins (1% BSA/PBS) for 2 hr. Slides were incubated with anti-Oct4 polyclonal primary antibody (SC-8629; Santa Cruz Biotechnology, USA) diluted 1:100 with 0.1% BSA/PBS solution, overnight at 4°C. Afterwards, tissues were incubated with secondary antibody, anti-goat HRP conjugated (Abcam, USA), overnight at 4°C. Then enzyme development was performed with DAB/H$_2$O$_2$ complex for 10 min in room temperature and in the absence of light which provides a brownish precipitation. All the stages were similar in negative controls except for the omission of the primary antibody.

**Results**

**Detecting Oct4 expression in FFPE samples of bladder tumors**
We used a semi-quantitative RT-PCR approach to detect Oct4 expression in FFPE samples of bladder and also to compare the level of Oct4 expression among different grades.
Evaluating the Expression of Oct4

and stages of the tumor samples (Figure 1). Briefly, the intensity of the Oct4 and β2m bands was measured by Uvitech software, and the ratio of Oct4/β2m expression was considered as the intensity of the gene expression. Initially, the median of the expression among all samples were determined and the expression above the median was considered as high and the ones below the median considered as low expression. Among 52 FFPE samples, 23 samples (44%) had high expression, 24 (46%) had low expression, and 5 (10%) had no expression. The samples with no Oct4 expression were classified in a separate group termed as “No expression” group.

One-Way ANOVA test revealed a significant correlation between the average of Oct4 expression and the grade of tumors (P< 0.05; Figure 2A). Due to the few number of cases in some stages, we had to classify the samples with Tis, Ta, and T1 stages in one group named “Low stage” and the other samples with T2, T3, and T4 stages in another group named “High stage”. Using the Mann-Witney analysis our data demonstrated a significant correlation (P< 0.05) between the expression level of Oct4 and the stage of the tumors (Figure 2B).

Oct4 is mostly localized within the cytoplasm of tumor cells

Next, we employed IHC to examine whether Oct4 is also expressed at the protein level and also to determine its tissue and subcellular distribution. As it is evident in Figure 3A, there are some Oct4-positive cells in tissue sections showing a cytoplasmic signal for Oct4. However, there is also a rare subpopulation of cells with strong immunoreactivity within their nuclei. There was no immunoreactivity signal within the cells in which the Oct4 antibody was eliminated during IHC (The negative control, Figure 3B), confirming the authenticity of the observed signal for Oct4.

Figure 1. Reverse transcription polymerase chain reaction analysis of the expression of Oct4 and B2M in FFPE samples of 4 patients; consecutive numbers show recurrent samples of the same patient. The 100 bp DNA ladder is used as molecular size marker

Figure 2. Relative expression of Oct4 in bladder tumors with different grades (A) and stages (B). Values are shown as the mean ±SD. Low stage=stages Tis, Ta, and T1. High stage=stages T2, T3, and T4
Figure 3. Immunohistochemistry results showing the tissue distribution and subcellular localization of Oct4. Brown signals show the mostly cytoplasmic localization of Oct4 protein (A); Negative control with no primary antibody treatment (B). Slides were counterstained with Hematoxyline and Eosine

Discussion

Bladder cancer has high incidence and recurrence rates in Iran; particularly it is the 3rd most frequent cancer in men (23). Thus, early detection and finding reliable methods for screening high risk cases is of vital importance. The current methods of bladder cancer diagnosis are urine cytology and cystoscopy. Urine cytology is a procedure with 95% specificity but low sensitivity, especially in low-grade tumors. Cystoscopy is the current gold-standard method for bladder cancer detection, but it is an invasive and expensive procedure with low specificity and sensitivity in detecting superficial tumors (24). Therefore, there have been lots of efforts in the field to find non-invasive, sensitive, and specific molecular markers for bladder cancer. The molecular markers that could be easily traced in the urine of patients are of special interest (25, 26). The main aim of finding such tumor markers is to provide primarily a way to detect and classify tumors more accurately and ultimately to provide a molecular target for gene-based therapy.

Prompted with the cancer stem cell hypothesis, we have previously reported the expression of a well-known stem cell marker, Oct4, in bladder cancer. Furthermore, the study also revealed a significantly strong correlation between the expression level of Oct4 and the tumor/non-tumor state of the samples (10).

As a stem cell specific transcription factor, Oct4 plays a vital role in pluripotency, self-renewal and prevention of differentiation of inner cell mass (ICM). Based on ours and other reports, Oct4 is also expressed in several tumors including testis, bladder, uterus, breast, and ovarian cancers (10, 27-32). Following unexpected detection of Oct4 in several cancers, it is currently considered as a molecular target for CSC-directed gene therapy.

In the current study, we have extended our previous study and evaluated the level of Oct4 expression in FFPE archival collections through a retrospective study. Due to the unlimited supply of FFPE samples in most hospitals, the current approach would provide some advantages compared with the works using fresh biopsies or surgical materials. However, in practice, we encountered some problems in following-up the current status of most patients, mostly due to the lack of a good recording system to contact the patients or their families. Therefore, instead of randomly selecting some samples and correlating the Oct4 expression with the clinical outcome of each stage and grade, we had to restrict our
work to those patients whom their records and outcomes were available.

Based on our data, a significant correlation between the expression level of Oct4 and the grade and stage of the samples are evident. These findings are consistent with our previous report suggesting the suitability of Oct4 expression as a molecular marker for the diagnosis of bladder tumors (10). The current investigation also provides some data supporting the suitability of Oct4 as a prognostic molecular marker to predict the malignant nature of bladder cancers. This claim, however, needs to be further examined with a bigger population size comprising a good sample size for each grade and stage subgroups.

In IHC experiment, we detected Oct4 mostly in the cytoplasm of the tumor cells, a finding which is consistent with our previous report on differential expression of Oct4 variants in pluripotent vs. non-pluripotent cell lines (17). The expression of the main variant of Oct4, Oct4A, is restricted in pluripotent cells, where the encoded protein is depicted in the nuclei of the cells. The Oct4B variant differs from the Oct4A by lacking exon 1 and having a bigger exon 2 and is preferentially detected in the cytoplasm of tumor cells. The later finding confirms the identity of the expressed Oct4 in the bladder tumors as Oct4B variant. However, there was a rare subpopulation of cells with nuclear staining for Oct4. The latter cells are probably the cancer stem cells or normal adult bladder stem cells which reside within the tumor tissues.

All together, our data provide strong evidence to support the correlation of Oct4 expression with the malignant behavior of bladder cancer.

Conclusion
When these data are taken together, our study for the first time demonstrates a differential expression pattern of Oct4 in FFPE tissues of bladder cancer with different progression states. This could potentially have a practical usefulness in prognosis and/or therapy of the tumor.

Acknowledgment
We are grateful to Ms. Shabnam Golshan for her assistance. This work was supported, in part, by a research grant from the UNRC, Labbafi-Nejad Medical Centre. All the samples were provided by Shahid Labbafi-Nejad Medical Centre, Tehran, Iran.

References
1. Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, et al. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization and p53 analyses. Hum Pathol 2006; 37:143–151.
2. Junker K, Wolf M, Schubert J. Molecular clonal analysis of recurrent bladder cancer. Oncol Rep 2005; 14:319–323.
3. Gil J, Stembalska A, Pesz KA, Sasiadek MM. Cancer stem cells: the theory and perspectives in cancer therapy. J App Genet 2008; 49:193–199.
4. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23:7274–7282.
5. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51:1–28.
6. Webster JD, Yuzbasiyan-Gurkan V, Trosko JE, Chang CC, Kiupel M. Expression of the embryonic transcription factor Oct4 in canine neoplasms: A potential marker for stem cell subpopulations in neoplasia. Vet Pathol 2007; 44:893–900.
7. Lengner CJ, Camargo FD, Hochedlinger K, Welstead GG, Zaidi S, Gokhale S, et al. Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 2007; 1:403–415.
8. Okumura-Nakanishi S, Saito M, Niwa H, Ishikawa F. Oct-3/4 and Sox2 regulate Oct-3/4 gene in embryonic stem cells. J Biol Chem 2005; 280:5307–5317.
9. Sun Y, Li H, Yang H, Rao M, Zhan M. Mechanisms controlling embryonic stem cell self-renewal and differentiation. Crit Rev Eukaryot Gene Expr 2006; 16:211–231.
10. Atlasi Y, Mowla SJ, Ziaee SAM, Bahrami AR. Oct4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007; 120:1598–1602.
11. Card DA, Hebbar PB, Li L, Trotter KW, Komatsu Y, Mishina Y, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cel Biol 2008; 28:6426–6438.
12. Campbell PA, Perez-Iratxeta C, Andrade-Navarro MA, Rudnicki MA. Oct4 targets regulatory nodes to modulate stem cell function. PLoS ONE 2007; 2:e553.
13. Van den Berg D, Snoek T, Mullin NP, Yates A, Bezstarosti K, Demmers J, et al. An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell 2010; 6:369–381.
14. Pardo M, Lang B, Yu L, Prosser H, Bradley A, Babu MM, et al. An expanded Oct4 interaction network: implications for stem cell biology, development, and disease. Cell Stem Cell 2010; 6:382–395.
15. Asadi MH, Mowla SJ, Aleyasin SA, Asadzadeh J, Atlasi Y. Oct4B1, a novel spliced variant of Oct4, is highly expressed in gastric cancer and acts as an anti-apoptotic factor. Int J Cancer 2011; 128:2645-2652.
16. Tai MH, Chang CC, Kulpel M, Webster JD, OlsonLK, Trosko JE. Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005; 26:495–502.
17. Atlasi Y, Mowla SJ, Ziaee SAM, Gokhale PJ, Andrews PW. Oct4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells 2008; 26:3068-3074.
18. Xu K, Zhu Z, Zeng F. Expression and significance of Oct4 in bladder cancer. J Huazhong Univ Sci Technolog Med Sci. 2008; 27(6):675-677.
19. Trosko JE, Tai MH. Adult stem cell theory of the multi-stage, multimechanism theory of carcinogenesis: Role of inflammation on the promotion of initiated stem cells. Contrib Microbiol 2006; 13:45-65.
20. Pan GJ, Chang ZY, Scholer HR, Pei D. Stem cell pluripotency and transcription factor Oct4. Cell Research 2002; 12:321-329.
21. Blast the human Genome. Available at: http://www.ncbi.nlm.nih.gov/genome/seq/hsBlast.html
22. Sambrook J, Russel DW. Molecular cloning a laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; 2001.
23. Website of International Agency for Research on Cancer: http://globocan.iarc.fr/
24. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer, urolonc. 2009; 1:1-7.
25. Kausch I, Bohle A. Molecular aspects of bladder cancer: III. Prognostic markers of bladder cancer. Eur Urol 2002; 41:15-29.
26. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160:645-659.
27. Boiani M, Scholer HR. Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol 2005; 6:872-884.
28. Babaie Y, Herwig R, Greber B, Brink TC, Wruck W, Groth D, et al. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells 2007; 25:500-510.
29. Jin T, Branch DR, Zhang X, Qi S, Youngson B, Goss PE. Examination of POU homeobox gene expression in human breast cancer cells. Int J Cancer 1999; 81:104-112.
30. Cheng L, Thomas A, Roth LM, Zheng W, Michael H, Karim FW. Oct4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol 2004; 28:1341-1346.
31. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. Oct4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol 2004; 28:935-940.
32. Matthai C, Horvat R, Noe M, Nagele F, Radjabi A, van Trotsenburg M. Oct4 expression in human endometrium. Mol Hum Reprod 2006; 12:7-10.